ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimabs Unique Mechanism of Action in the Treatment of Atopic Dermatitis
ASLNDelisted Stock | USD 0.60 0.03 4.76% |
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Aslan |
SAN MATEO, Calif. and SINGAPORE, June 23, 2023 ASLAN Pharmaceuticals , a clinical-stage, immunology-focused...
Read at globenewswire.com
Aslan Pharmaceuticals Fundamental Analysis
We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Aslan Pharmaceuticals is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Aslan Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aslan Pharmaceuticals Related Equities
ANTX | AN2 Therapeutics | 21.90 | ||||
GLUE | Monte Rosa | 13.72 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
IOBT | IO Biotech | 4.71 | ||||
CMPX | Compass Therapeutics | 4.49 | ||||
CTMX | CytomX Therapeutics | 3.92 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
ADAG | Adagene | 1.30 | ||||
ASMB | Assembly Biosciences | 1.25 | ||||
AGIO | Agios Pharm | 1.24 | ||||
ACHL | Achilles Therapeutics | 0.93 | ||||
ACRV | Acrivon Therapeutics, | 0.80 | ||||
ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
AVTE | Aerovate Therapeutics | 0.38 | ||||
IVA | Inventiva | 1.12 | ||||
GPCR | Structure Therapeutics | 1.78 | ||||
ERAS | Erasca | 2.05 | ||||
MLYS | Mineralys Therapeutics, | 2.59 | ||||
NAMS | NewAmsterdam Pharma | 4.57 | ||||
TIL | Instil Bio | 9.39 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |